Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Human Factors

Date Submitted: Nov 27, 2024
Open Peer Review Period: Dec 3, 2024 - Jan 28, 2025
Date Accepted: Apr 4, 2025
(closed for review but you can still tweet)

The final, peer-reviewed published version of this preprint can be found here:

Personal Health Record Software for Neuroendocrine Tumors: Patient-Centered Design Approach

Hourcade JP, O'Rorke M, Chrischilles E, Rudzianski NJ, Gryzlak B, Peterman K, Ortman C, Wolstencroft S, Bean M, Gellerman E, Mailman JA, Wahmann M

Personal Health Record Software for Neuroendocrine Tumors: Patient-Centered Design Approach

JMIR Hum Factors 2025;12:e68788

DOI: 10.2196/68788

PMID: 40460293

PMCID: 12151452

Designing Personal Health Record Software for Rare Diseases: A Patient-Centered Approach in Neuroendocrine Tumors

  • Juan Pablo Hourcade; 
  • Michael O'Rorke; 
  • Elizabeth Chrischilles; 
  • Nicholas J. Rudzianski; 
  • Brian Gryzlak; 
  • Kerry Peterman; 
  • Chris Ortman; 
  • Sam Wolstencroft; 
  • Margaret Bean; 
  • Elyse Gellerman; 
  • Josh A. Mailman; 
  • Maryann Wahmann

ABSTRACT

Background:

Personal Health Record (PHR) software has the potential of aiding with patient engagement and data collection in longitudinal research to better understand the long-term impact of treatments on patients with rare medical conditions. Neuroendocrine tumors (NETs) represent a rare condition with unique challenges related to symptom management, treatment tracking, and patient-provider communication.

Objective:

This study aimed to design, develop, and evaluate PHR software tailored for patients with NETs as part of a longitudinal research study. Our goal was to create a patient-centered PHR that supports both self-management and research data collection.

Methods:

This included activities spanning the entire development lifecycle from identifying user requirements through focus groups and surveys, iterative prototype refinement via cognitive walkthroughs, and usability testing of the functional PHR system. Feedback from patient advocacy organizations and clinical experts further informed PHR development.

Results:

The resulting PHR allows NET patients to access condition-specific information, track symptoms, monitor treatment regimens, and share data with healthcare providers. Patients valued the ability to visualize personal health trends and patterns over time, enhancing both self-management and communication with medical teams. Usability testing indicated high levels of patient satisfaction with the system’s functionality and design.

Conclusions:

The development of this PHR demonstrates the value of engaging patients in the design process to ensure that health technologies address real-world needs. Our approach provides a model for designing PHR systems for other rare conditions, highlighting the importance of patient-centered design in supporting both clinical care and longitudinal research. Clinical Trial: Not applicable.


 Citation

Please cite as:

Hourcade JP, O'Rorke M, Chrischilles E, Rudzianski NJ, Gryzlak B, Peterman K, Ortman C, Wolstencroft S, Bean M, Gellerman E, Mailman JA, Wahmann M

Personal Health Record Software for Neuroendocrine Tumors: Patient-Centered Design Approach

JMIR Hum Factors 2025;12:e68788

DOI: 10.2196/68788

PMID: 40460293

PMCID: 12151452

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.